Investor Presentation Q1-Q3 2020

60 Investor presentation First nine months of 2020 Biopharm sustained growth outlook is supported by innovation and utilisation of core capabilities Internal and external innovation to drive long-term growth Core capabilities within research and development to drive long-term growth 24 Novo Nordisk® Bringing internal innovation to market by pipeline progression Ensuring future growth by leveraging external innovation Exploring new technologies by utilising added research platforms Leveraging deep biological understanding for future growth

View entire presentation